Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exubera in Diabetics With Chronic Asthma
NCT00139659Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2003
- Primary completion
- Oct 2008
- Modality
- Biologic
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of insulin human in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Pfizer. Primary endpoints: Annualized Rate of Change for Forced Expiratory Volume in 1 Second at 52 weeks, Annualized Rate of Change for Hemoglobin-adjusted Carbon Monoxide Diffusion Capacity at 52 weeks and 2 more. Started Jan 2003; status: completed.
02
Drugs
insulin human
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00139659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00139659.